Metagenomi (NASDAQ:MGX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Metagenomi (NASDAQ:MGX) from a hold rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Metagenomi Stock Down 4.4%

Shares of MGX stock opened at $1.41 on Friday. The stock has a 50-day simple moving average of $1.56 and a 200 day simple moving average of $1.91. Metagenomi has a fifty-two week low of $1.23 and a fifty-two week high of $3.95. The stock has a market capitalization of $52.86 million, a P/E ratio of -0.59 and a beta of 0.45.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.02). Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%.The business had revenue of $3.91 million during the quarter, compared to the consensus estimate of $7.33 million. On average, sell-side analysts anticipate that Metagenomi will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On Metagenomi

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Pura Vida Investments LLC lifted its stake in Metagenomi by 260.1% during the second quarter. Pura Vida Investments LLC now owns 952,134 shares of the company’s stock valued at $1,409,000 after buying an additional 687,743 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of Metagenomi in the fourth quarter worth approximately $55,000. Panagora Asset Management Inc. acquired a new stake in shares of Metagenomi during the fourth quarter valued at approximately $53,000. Man Group plc acquired a new stake in shares of Metagenomi during the third quarter valued at approximately $125,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Metagenomi in the 3rd quarter valued at approximately $64,000.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.